Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the efficacy of escitalopram (30 mg/day) in two parallel groups (randomization
ratio, escitalopram 2/placebo 1).